Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chiasma, Inc.

https://chiasma.com/

Latest From Chiasma, Inc.

Analysts Impressed By Amryt As EB Drug Action Date Approaches

Amryt has set out its future plans to the investment community with much depending on the successful relaunch of its just-acquired acromegaly drug Mycapssa and a potential FDA approval for its epidermolysis bullosa gel Filsuvez.

Business Strategies Rare Diseases

Gilead’s Long-Acting HIV Drug Among Latest EU Filings

The European Medicines Agency has added seven new products to its list of medicines that are under review for potential EU marketing authorization.

Europe Drug Review

Orphan Drugs Nefecon, Maribavir & Copanlisib Among New EU Filings

Marketing applications for two generic versions of the multiple sclerosis blockbuster, Tecfidera, are also under review by the European Medicines Agency.

Europe Drug Review

Amryt Predicts $1bn Revenues After Chiasma Acquisition

The Irish drugmaker will have three approved commercial products for rare diseases – Mycapssa, Lojuxta and Myalept – with a potential fourth therapy on the way now Filsuvez has been filed for butterfly skin.

M & A Rare Diseases
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
  • Biotechnology
    • Large Molecule
UsernamePublicRestriction

Register